| Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients V Gopalakrishnan, CN Spencer, L Nezi, A Reuben, MC Andrews, ... Science 359 (6371), 97-103, 2018 | 3847 | 2018 |
| Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade SC Wei, JH Levine, AP Cogdill, Y Zhao, NAAS Anang, MC Andrews, ... Cell 170 (6), 1120-1133. e17, 2017 | 1150 | 2017 |
| Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma RN Amaria, SM Reddy, HA Tawbi, MA Davies, MI Ross, IC Glitza, ... Nature medicine 24 (11), 1649-1654, 2018 | 689 | 2018 |
| Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response CN Spencer, JL McQuade, V Gopalakrishnan, JA McCulloch, M Vetizou, ... Science 374 (6575), 1632-1640, 2021 | 418 | 2021 |
| Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies SC Wei, NAAS Anang, R Sharma, MC Andrews, A Reuben, JH Levine, ... Proceedings of the National Academy of Sciences 116 (45), 22699-22709, 2019 | 285 | 2019 |
| Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised … RN Amaria, PA Prieto, MT Tetzlaff, A Reuben, MC Andrews, MI Ross, ... The Lancet Oncology 19 (2), 181-193, 2018 | 270 | 2018 |
| Hallmarks of response to immune checkpoint blockade AP Cogdill, MC Andrews, JA Wargo British journal of cancer 117 (1), 1-7, 2017 | 253 | 2017 |
| Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade MC Andrews, CPM Duong, V Gopalakrishnan, V Iebba, WS Chen, ... Nature medicine 27 (8), 1432-1441, 2021 | 252 | 2021 |
| Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade N Jacquelot, T Yamazaki, MP Roberti, CPM Duong, MC Andrews, ... Cell research 29 (10), 846-861, 2019 | 198 | 2019 |
| Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium RN Amaria, AM Menzies, EM Burton, RA Scolyer, MT Tetzlaff, ... The Lancet Oncology 20 (7), e378-e389, 2019 | 196 | 2019 |
| MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells LJ Vella, A Pasam, N Dimopoulos, M Andrews, A Knights, AL Puaux, ... Cancer immunology research 2 (4), 351-360, 2014 | 145 | 2014 |
| Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy S Bowyer, P Prithviraj, P Lorigan, J Larkin, G McArthur, V Atkinson, ... British Journal of Cancer 114 (10), 1084-1089, 2016 | 133 | 2016 |
| The nitric oxide system in glucocorticoid-induced hypertension JA Whitworth, CG Schyvens, Y Zhang, MC Andrews, GJ Mangos, JJ Kelly Journal of hypertension 20 (6), 1035-1043, 2002 | 112 | 2002 |
| Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases S Parakh, JJ Park, S Mendis, R Rai, W Xu, S Lo, M Drummond, C Rowe, ... British journal of cancer 116 (12), 1558-1563, 2017 | 110 | 2017 |
| Apocynin but not allopurinol prevents and reverses adrenocorticotropic hormone-induced hypertension in the rat Y Zhang, MMK Chan, MC Andrews, TA Mori, KD Croft, KUS McKenzie, ... American Journal of Hypertension 18 (7), 910-916, 2005 | 101 | 2005 |
| The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression L Huang, S Malu, JA McKenzie, MC Andrews, AH Talukder, T Tieu, ... Clinical Cancer Research 24 (14), 3366-3376, 2018 | 88 | 2018 |
| The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors CN Spencer, V Gopalakrishnan, J McQuade, MC Andrews, B Helmink, ... Cancer Research 79 (13_Supplement), 2838-2838, 2019 | 80 | 2019 |
| Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure MP Smith, EJ Rowling, Z Miskolczi, J Ferguson, L Spoerri, NK Haass, ... EMBO molecular medicine 9 (8), 1011-1029, 2017 | 71 | 2017 |
| Human perforin mutations and susceptibility to multiple primary cancers JA Trapani, KYT Thia, M Andrews, ID Davis, C Gedye, P Parente, ... Oncoimmunology 2 (4), e24185, 2013 | 70 | 2013 |
| Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy CP Vellano, MG White, MC Andrews, M Chelvanambi, RG Witt, ... Nature 606 (7915), 797-803, 2022 | 60 | 2022 |
